Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

September 10th 2022

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor­–positive metastatic breast cancer.

Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

September 10th 2022

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Abemaciclib Plus Trastuzumab Results in Numerical OS Improvement Vs SOC in HR+, HER2+ Advanced Breast Cancer

September 10th 2022

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

September 10th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

First-line Dalpiciclib Significantly Improves PFS Outcomes for Patients With HR+/HER2– Advanced Breast Cancer

September 9th 2022

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

Oleclumab/Durvalumab Plus Chemotherapy Combo Fails to Reach Clinical Benefit End Point in Advanced TNBC

September 9th 2022

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

Sacituzumab Govitecan Produces Significant Efficacy Benefits in Pretreated HR+/HER2- Metastatic Breast Cancer

September 9th 2022

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

September 9th 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

September 8th 2022

Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.

Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers

September 8th 2022

Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.

Future Directions in HR+ Breast Cancer Management

September 7th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

Clinical and Practical Implications of the Breast Cancer Index

September 7th 2022

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer

September 5th 2022

Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.

Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer

September 2nd 2022

Sacituzumab govitecan displayed encouraging progression-free survival rates compared with single-agent chemotherapy in patients with locally recurrent inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer, according to findings from the phase 3 TROPiCS-02 study.

Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care

September 2nd 2022

Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.

Metastatic Breast Cancer Enters a New Era of HER2 Classification

September 2nd 2022

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy

September 1st 2022

Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.

Sequencing Therapy in MBC in Second Line and Beyond

September 1st 2022

Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.

Audience Q&A: Future Directions in Breast Cancer Care

August 31st 2022

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

Trastuzumab Deruxtecan Approval for HER2-Low Breast Cancer Sparks Bright Future for ADCs

August 29th 2022

Shanu Modi, MD, discusses the significance of the approval of trastuzumab deruxtecan for patients with HER2-low breast cancer.